CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings

Background Studies have demonstrated increased risk of major atherothrombotic events in CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with clopidogrel after percutaneous coronary intervention (PCI). We sought to evaluate real‐world outcomes with the clinical implementat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Amber L. Beitelshees, Cameron D. Thomas, Philip E. Empey, George A. Stouffer, Dominick J. Angiolillo, Francesco Franchi, Sony Tuteja, Nita A. Limdi, James C. Lee, Julio D. Duarte, Rolf P. Kreutz, Todd C. Skaar, James C. Coons, Jay Giri, Caitrin W. McDonough, Rachel Rowland, James M. Stevenson, Thuy Thai, Mark R. Vesely, Jacob T. Wellen, Julie A. Johnson, Almut G. Winterstein, Larisa H. Cavallari, Craig R. Lee
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley 2022-02-01
Colecção:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Assuntos:
clopidogrel
CYP2C19
pharmacogenetics
Acesso em linha:https://www.ahajournals.org/doi/10.1161/JAHA.121.024159
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados